the higher doses of Ara-C ( 5 5 mg/kg), profound disruption of cerebellar cytoarchitecture occurred; both gross neurologic abnormalities and marked growth retardation developed in adult animals which survived.
Speculation
There are problems with assuming direct or unifying structure-action relations among chemotherapeutic agents. Efforts should be exerted to determine accurately the kinetic parameters and therapeutic index for each new drug as it comes into use. The data presented here show that, in doses effective against DNA viral infection, the purine nucleosides Ara-A and Ara-Hx did not substantially impair DNA replication and inhibit cellular function in the rat cerebellum in comparison to the pyrimidine nucleoside, Ara-C. It is interesting to speculate that Ara-A may be incorporated preferentially into viral nucleic acid by viral enzymes. as in the case of 5-bromodeoxycytidine by herpes virus-infected cells.
Assuming that Ara-A is proven further to be an effective antiviral compound, the lack of toxicity upon rapidly replicating cells of various systems gives it an obvious advantage in comparison with other compounds which inhibit DNA viral replication.
In part, advances in molecular biology have come about as the result of detailed study of biochemical and genetic events. Methods of study have included the use of metabolic inhibitors, some of which have been found to block synthesis of new specific viral structural materials resulting in selective suppression of replicative processes. By this means, a moderate number of prospective chemotherapeutic agents have been made available for study in viral infections of animals and for potential clinical use in humans. One of the limitations of use of antiviral compounds is directly the result of interaction between the cells of the host and the antibiotic. Thus, there are many examples of chemicals which, in in vitro systems, effectively or totally prevent viral replication, but cannot be used in clinical trials beause of cellular toxicity. The chances of cellular damage in rapidly developing organs in the immature host, with permanent sequelae as a result, are greater than in the mature animal. Therefore, we agree with Langman and associates (14) that there are dangers implicit in treating newborn infants for viral infections with compounds that are known to inhibit or interrupt DNA replication, except in the case where inhibition is specific for viral replication and cellular replication is spared (7) .
The treatment of herpetic and cytomegalovirus infections in neonates with inhibitors of DNA synthesis occurs in a setting of rapid nucleic acid synthesis and cell division. Repair may quickly follow suppression of cellular DNA synthesis in some organs; for example, in the gastrointestinal and urinary tracts. However, in organs of limited regenerative capacity, such as the central nervous system, permanent damage may occur. This is particularly true where cellular proliferation is strongly associated with differentiation and ontogeny (1).
In the postnatal cerebellum of smaller animals, there occurs extensive replicative activity along with cellular migration and maturation (9) . In rodents, interference with the rapid development of the postnatal cerebellum may result from various injuries, including that induced by the use of cyclophosphamide (Cytoxan) (1 8), FUDR (1 4) and Ara-C (8) (Cytosar (28) (25) . This drug has low toxicity for small animals (13), but its effects upon postnatal development have not been examined. Therefore, this study was designed t o compare the effects of Ara-A and its deaminated derivative, Ara-Hx, with those of Ara-C on the newborn rat. The rat was a species chosen for this study because much is known about the normal development including cerebellar growth and maturation (27) .
Ara-A is known t o be rapidly deaminated by the mammalian enzyme, adenosine deaminase t o Ara-Hx (4). Therefore, the in vitro activity of Ara-A may depend upon the plasma and tissue concentration of Ara-Hx. For this reason, we decided t o examine the antireplicative activity of Ara-Hx as well as Ara-A.
MATERIALS AND METHODS
Different duplicate litters of 2-day-old Sprague-Dawley rats received injections intraperitoneally with a 1-cc tuberculin syringe filled with lactated Ringer's solution containing either Ara-A (29) (at final dosage of 3, 5 , 10, 20, and 3 0 mg/kg), Ara-Hx (29) (10 and 20 mg/kg), or Ara-C (30) (3, 5 , 10, and 15 mg/kg). Animals received injections once daily for 4 days.
A control litter received injections of the vehicle with drugs omitted.
The animals were weighed in a pan balance every 4th day until the age of 6 0 days. They were observed daily for fatalities and those obviously injured by an injection were discarded from the study. All were examined for evidence of poor feeding, pallor, lethargy, and skin infection. Dying animals were removed from cages when possible t o avoid maternal cannibalism. These were scored as fatalities. Individuals were selected at random from each group and killed at 6, 10, 14, 18, and 22 days of age. Brains of experimental and control animals were rapidly removed and fixed in 10% buffered formalin for 3 days. They were then divided by a precise sagittal cut, and the dimensions of t h e cerebellum measured with a micrometer. One-half of each brain was embedded in paraffin and sagittal sections were cut and stained with hematoxylin and eosin. The other fixed hemicerebellum was weighed on a Mettler balance.
T o determine the effect of the drugs on motor development, locomotion was evaluated by a simplification of the methods of Wallace and Altman (26) and of Altman et al. (2). All litters were observed daily up t o the age of 5 weeks (midadolescence).
Later, another group were given 50 mg/kg Ara-A and observed for mortality alone.
RESULTS
The lethality of the three arabinosyl nucleosides t o suckling rats is shown in Table 1 . All fatalities occurred before t h e 18th postnatal day. There were no fatalities among controls, nor were there any drug-induced deaths for those animals treated with less than 20 mg/kg Ara-A. Mortalities of 3% and 12%, respectively, were observed for Ara-A at 20 mg/kg and 30 mg/kg, but these were not statistically significant ( X 2 , P < 0.05). Animals treated with either Ara-A or Ara-Hx showed n o signs of poor feeding, lethargy, or pallor. They matured at a normal rate and, by the 4 t h week, were identical with controls. All animals treated with lowest dose of Ara-C (3 mg/kg) developed normally. Those receiving higher doses of Ara-C developed pustules over the body and head, appeared weak and pale, and fed poorly. In those which survived t o adolescence, the pustules crusted and cleared, but hair growth was retarded and coarse.
Comparative growth curves are shown in Figure 1 . Included are the control group and the groups receiving Ara-A, 30 mg/kg; Ara-Hx, 20 mg/kg; and Ara-C, 3, 5, and 10 mg/kg doses. The 15 mg/kg Ara-C group is not included, for all animals were dead by the 10th day. Animals receiving Ara-C failed t o grow compared with the saline control, Ara-A, and Ara-Hx animals. An analysis of variance ( F test) revealed no statistically significant difference among any of the controls, Ara-A, or Ara-Hx populations (P < 0.05).
Figure 2 demonstrates cerebellar weight during the first 3 weeks of life in controls, and in groups treated with Ara-A, Ara-Hx, and AraC. Two populations are evident with neither arabinosyl purine affecting cerebellar growth compared with saline-injected controls (Fig. 2 , A and B) . At 15 mg/kg Ara-C, there was little, if any, growth before death at 10 days (Fig.  2C ). At 3 , 5, and 10 mg/kg Ara-C, there was markedly retarded growth of the cerebellum. However, at the lowest dose ( 3 mg/kg), the animals did repair and were not damaged as they reached maturity by any of the variables measured. None of the drugs induced grossly obvious impairment in cerebral growth; however, the brains were not weighed.
Comparative histopathology further confirmed marked differences in the effects of the nucleosides upon the cerebellum as shown in Figure 3 ' Ara-A: adenine arabinoside; Ara-Hx: hypoxanthine arabinoside; Ara-C: cytosine arabinoside.
Twoday-old animals received intraperitoneal injections on postnatal days 2 through 5, containing dose indicated.
All dead by 10 days. 30 mg/kg, Ara-C 5 mg/kg, or vehicle alone and killed on day 6, 10, 18, or 2 2 as discussed below.
ARABINOSYL NUCLEOSIDES
By the 6th day of postnatal life, the external granulayer (EGL) of the cerebellum is a densely packed stratum 6-8 cells thick. It is separated from the Purkinje cell layer by a definite molecular layer (ML). The Purkinje cells are oriented externally and ordered regularly at the outer surface of the sparsely populated internal granular layer (IGL). The cerebella of animals treated with Ara-A (Fig. 3, A 2 , B2, and C 2 ) were of normal appearance and were identical t o controls (Fig. 3, A l , B I , and C I ) . In contrast, cerebella of Ara-C-treated animals were markedly abnormal as shown in Figure 3A3 . The EGL was absent, Purkinje cells were dispersed throughout the ML and cells of the IGL were found in various areas. Moderate abnormalities were present at even the lowest dose, 3 mg/kg.
In the 10-day old animals, cellularity and organization within the cerebellum of those receiving Ara-A and Ara-Hx were identical with controls. In animals receiving 3 mg/kg Ara-C, repair was obvious at 10 days in the EGL so that it now resembled the cerebellum of day 6 control animals. Purkinje cells, however, remained in disarray. In contrast, only minimal repair had taken place in animals receiving greater than 3 mg/kg Ara-C, and there was obvious disorganization.
By day 18 and beyond, the control and Ara-A-treated animals had an essentially adult cerebellum with a svarse EGL. a broad ML, and a densely packed IGL (Fig. 3, Cl and C2 ). 1; contrast, cerebella of Ara-C-treated animals still demonstrated varying degrees of immaturity with persistent disorganization at doses higher than 3 mg/kg (Fig. 3C3) . Purkinje cells remained aberrant and small clusters and rows of ectopic cells were present within the molecular layer. At only the lowest dose of Ara-C ( 3 mg/kg) was there enough repair t o approach normal cytoarchitecture at 22 days and still there was immaturity.
Behavioral and developmental observations largely confirmed the histopathology. Animals were observed qualitatively and quantitatively for activity, resting tremor, hind foot dragging, ataxia, and falling. After the 3rd postnatal week, all of the Ara-A and Ara-Hx-treated animals, as well as animals treated with 3 mg/kg Ara-C, were normal in their development and behavior at this stage of maturation and could not be differentiated from control animals. The animals receiving 5-10 mg/kg Bra-C were markedly different from controls. Those which survived developed conspicuous ataxia, hind leg dragging, and "circling." These findings seemed t o be more severe relative t o increase in dose. In addition, all survivors in the 1 0 mg/kg group were runted, hairless, and showed signs of human toxicity of Ara-A has been limited t o nausea and lack skin infection. of weight gain during intravenous infusion (6) . No serious toxicity has been encountered from courses of therapy extending over 14-21day periods in children or adults (6).
DISCUSSION
At 5-10 times prevailing antiviral therapeutic doses, Gottlieb Cerebellogenesis follows similar patterns in all mammals and (10) has observed definite marrow suppression in patients birds (9) . There are subtle differences in the development of under treatment for leukemia. Here again, ~r a -A is much less the external granular layer, in interneural and Purkinje cell than Ara-C.
maturation, and in the growth rate in different parts of the Therefore, Ara-A, if Proven t o be a clinically effective cerebellum, among genera. In the primate, including the antiviral drug, may offer a choice in chemotherapy of large human, in contrast t o the rodent, most of these phenomena DNA viral infections. In any case, long term follow-up of occur months earlier and the period of most rapid growth treated neonates and young infants, particularly those who occurs before birth (23, 24) . ~h~~, the danger of using drugs receive toxic drugs, must be compared with untreated patients, that suppress D~~ replication in the newborn infant may be or t o patients receiving presumptively nontoxic antiviral diminished but absolutely not eliminated. Certainly, the .compounds. If Ara-A is effective in suppressing DNA viral possibility of such damage would favor the use of nontoxic mfections in neonates, then an opportunity is ~r o v i d e d t o compounds where there is a choice. such reasoning would make a direct comparison between presumptively effective have more importance in the treatment of infections when antiviral compounds, one of which has n o known human they have developed in premature infants, when human toxicity at prevailiizg doses. Only in this manner will one be cerebellar growth may be more sensitive to anti-^^^ able t o ascertain whether or not toxic antiviral compounds replicative activity. result in further damage in patients in whom the spectrum of These experiments have demonstrated obvious differences in is as a the the effect of two arabinosyl purines and an arabinosyl pyrimidine on the growth and development of newborn rats.
SUMMARY
Ara-A, given in excess of prevailing clinical doses (6) had n o apparent effect in the rat on mortality, body growth, cerebellogenesis, and behavior, in comparison with salineinjected controls. Neither did Ara-Hx. The importance of using Ara-Hx in these experiments is in demonstrating that neither Ara-A nor its deaminated metabolite had a demonstrable anti-DNA replicative effect. If Ara-A had demonstrated effect and Ara-Hx had not, at equal doses, it could be assumed that Ara-A was not completely deaminated in tissues. If both had demonstrated anti-DNA replicative effect, then the molecular Newborn rats treated with arabinosides of purine and pyrimidine were examined for growth, development, and neurologic abnormalities as well as growth, maturation, and cellular organization of the cerebellum; Ara-A, Ara-Hx, and saline-injected animals were normal, whereas Ara-C-injected animals frequently died and survivors had histologic as well as gross abnormalities. A~~-A to A~~-H~, it was important also to examine it for 3. Breedan, C. J., Hall, T. C., and Tyler, H. R.: Herpes simplex encephalitis treated with systemic 5-iodo-2'-deoxyuridine. Ann.
toxicity, and to find it lacking.
Intern. Med., 65: 1050 (1966).
In marked contrast, when measured by the same parameters, 4. Brink, J. J., and Lepage, G. A,: Metabolism and distribution of Ara-C had profound effects which resulted in lack of suppression of bone marrow (12, 15, 22) and immune response (17) . These doses have been used t o treat viral infections in neonates (1 2, 15, 22) . A similar situation may exist in respect t o systemic viral chemotherapy with iododeoxyuridine (IUDR) in which the viral inhibiting dose may suppress cellular replication and produce serious toxicity (3, 5 , 2 0 ) .
The potential of damage t o the rapidly developing central nervous system by Ara-C, IUDR and FUDR and other similar drugs is obvious. However, without any available substitutes, Ara-C and IUDR have been used regularly in therapy of Herpes virus hominis and cytomegalovirus infection in neonates. No drug-induced central nervous system damage has been reported t o date. However, the background of central nervous system damage in such patients is high; therefore, specific associations between chemotherapeutic agents (drugs) and neuropathologic disorders are difficult t o make.
Ara-A is much less toxic than Ara-C. In vitro, toxicity t o the stable L cells (mouse fibroblasts) (21) and t o cultured human leukocytes (1 1, 19) is of the order of 1/100th that of Ara-C. It has been shown previously that doses of Ara-A much in excess of those used in these experiments produced only mild toxicity, primarily reversible weight loss, in adult small animals (13) . T o date, at doses between 5 and 20 mg/kg/24 hr, the
